Abbreviations & Acronyms BMI = body mass index CI = confidence interval CT = computed tomography GFR = glomerular filtration rate HDL = high-density lipoprotein HR = hazard ratio LDL = low-density lipoprotein Mets = metabolic syndrome NOS = Newcastle-Ottawa Scale OR = odds ratio TC = total cholesterol TG = triglyceride USG = ultrasonography Abstract: The objective of this study was to pool individual studies regarding the association of blood lipid profiles with urolithiasis to carry out a systematic review and meta-analysis. We searched MEDLINE, PubMed, Embase and Cochrane Library to identify the relevant studies up to November 2017. Studies that met all inclusion criteria were chosen, and a pooled analysis of the odds ratio between urolithiasis and dyslipidemia traits was calculated. A total of 11 observational studies (seven cross-sectional, three cohort, one case-control) with a total of 282 479 participants were examined. The overall pooled analysis of eight studies showed that high triglyceride was associated with increased estimated risk of urolithiasis (odds ratio 1.287, 95% CI 1.073-1.544; P = 0.007). Estimates of the total effect size were consistent in the sensitivity analysis. No evidence of publication bias was detected. The overall pooled analysis of nine studies showed low high-density lipoprotein was weakly associated with increased estimated risk of urolithiasis (odds ratio 1.171, 95% CI 1.010-1.358; P = 0.032). The sensitivity analysis showed conflicting results. No evidence of publication bias was detected. Three studies on the association between any dyslipidemia traits and urolithiasis showed a significant association (odds ratio 1.309, 95% CI 1.202-1.425; P < 0.001). The present meta-analysis showed that patients with higher triglyceride and lower high-density lipoprotein had an increased estimated risk of urolithiasis. A triglyceride-urolithiasis association was found to be more coherent and consistent compared with the high-density lipoprotein-urolithiasis association. Although somewhat contradictory results have been found, the meta-analysis is encouraging for evaluating urolithiasis as a systemic disorder. Further well-designed prospective randomized controlled or cohort studies are necessary to better elucidate the causal association of dyslipidemia and urolithiasis.
Introduction
Urolithiasis is a common disorder with an increasing prevalence rate. It is estimated that 5-15% of the USA population develops the symptomatic stone disease by the age of 70 years. [1] [2] [3] Despite its high prevalence and recurrence rate, the exact stone formation mechanisms are not yet elucidated. Many studies have shown that the prevalence of chronic diseases, including diabetes mellitus, obesity and hypertension, is high among stone formers compared with healthy counterparts. [4] [5] [6] [7] [8] [9] [10] Mets, a constellation of interrelated conditions including central obesity, impaired fasting glucose, dyslipidemia and hypertension, has raised keen interest for many diseases. Several studies have shown a positive association between Mets and urolithiasis. 11, 12 Dyslipidemia is an integral component of Mets, and current evidence suggests that dyslipidemic patients are more likely to have a higher prevalence of uric acid and calcium oxalate dihydrate calculi, as well as a lower urinary pH.
for 111 days compared with rats fed with standard laboratory chow. 15 Another animal model study by Fujii et al. showed that adiponectin inhibited the kidney crystal formation in Mets model mice through inhibition of inflammation and apoptosis. 16 These results are encouraging and helpful for designing the clinical studies evaluating the implication of lipid metabolism disturbances in nephrolithiasis, as well as finding new possible targets to prevent stone recurrence.
Either alone or as part of Mets, dyslipidemia and its possible association with urolithiasis was evaluated in some individual epidemiological studies, but they are not sufficient to arrive at a precise and coherent conclusion. The current scientific evidence has presented conflicting results on the association of dyslipidemia traits (HDL, LDL, TC) with urolithiasis. Accordingly, we decided to combine them in a systematic review and a meta-analysis design with the aim of shedding some light on a debate to determine whether there is an association between urolithiasis and serum lipid profile.
Methods

Literature search
The PubMed, MEDLINE, Embase and Cochrane databases were independently searched by two investigators to retrieve relevant studies published before October 2017. Discrepancies were resolved by consensus. The search was restricted to English language articles and studies of human participants. The search terms comprised of the following keywords: urolithiasis, nephrolithiasis, renal stone, renal calculus, renal calculi, kidney stone, kidney calculus, kidney calculi, dyslipidemia, cholesterol, TG, HDL, LDL and Mets.
Study inclusion and evaluation
Studies were included in the present meta-analysis if they met the following criteria: (i) the study design was observational; (ii) the outcome of interest was the prevalence or incidence of urolithiasis in patients with dyslipidemia; and (iii) OR or HR and corresponding 95% CIs (or data to calculate them) were reported.
The exclusion criteria included the following: (i) studies not providing data for OR calculation between dyslipidemia, its parameters (TG, HDL, LDL, TC) and urolithiasis; (ii) review or meta-analysis studies; (iii) comments, editorials, case reports, letters and meeting/congress abstracts; and (iv) animal experiments.
The term, dyslipidemia, was used as an increased TG and decreased HDL level in individual studies. Given that TG and HDL are the two main components of Mets, we tried to combine them separately instead of only calculating the association of dyslipidemia and urolithiasis. However, some studies just established the relationship of dyslipidemia and urolithiasis, and there was no detailed information about TG and HDL level, so we also made a calculation for the association of dyslipidemia (any disturbances in lipid profile) and urolithiasis.
Data included for each study were as follows: the first author's last name, year of publication, study design, country of study, population, time period, cohort size including males and females, age range, dyslipidemia traits, stone composition, adjustments for the calculation of dyslipidemia and urolithiasis association, and quality assessment of the studies.
Quality assessment
The included studies were assessed by the NOS. 17 The NOS is judged on three broad subscales using a star to identify high-quality choices: the selection of the study groups contains four items; the comparability of the groups comprises two elements, and the ascertainment of the exposure; or outcome of interest for observational studies includes three items. A score of ≤5 was regarded as low quality.
Statistical analysis
We carried out meta-analysis pooling of the relevant studies that met the inclusion criteria. Statistical heterogeneity among trials was assessed by using Cochran's Q and I 2 statistic, and a P-value <0.05 or I 2 value >50% was considered to be heterogeneous. 18 As individual studies were gathered from published literature and they did not share common effect size, we used a random effects model. We carried out sensitivity analysis to assess the robustness of the results in the present meta-analysis. The purpose of the sensitivity analysis was to evaluate the effect of a single study on the overall pooled estimates. The sensitivity analysis was carried out by omitting one study at a time, generating the pooled estimates and comparing with the original estimates. We assessed the presence of publication bias using funnel plots, which display the relationship between study size and effect size. To quantify the relationship, Begg and Mazumdar rank correlation and Egger's regression intercept tests were used. 19, 20 We further evaluated publication bias using Orwin's fail-safe N method. All statistical comparisons were two-sided, and a Pvalue <0.05 was considered statistically significant. All analyses were carried out using comprehensive meta-analysis Version.3 (Biostat, Englewood, NJ, USA).
Results
Literature search and study characteristics
We initially identified 719 studies, either in full publications or abstract forms, using the methodology and the search terms described above. Of the studies, 91 were reviews, 242 were animal model studies, 61 were child population studies and 230 had outcomes not relevant to the subject. A total of 95 publications were retrieved for further evaluation. Of these, 60 case reports, and 13 letters and editorials were excluded. Of the remaining 22 studies, 11 were eliminated because they did not report the mean value with standard errors or OR with 95% CIs or provide sufficient data to calculate them. Finally, 11 studies were included in the present meta-analysis. The details of the literature search are shown in Figure 1 .
The 11 selected studies contained 282 479 participants (ranging from 694 to 116 536). [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] They were published between 2008 and 2017. Of these, seven were cross-sectional studies, two were retrospective cohort studies, one was a prospective cohort study and one was a case-control study. As multivariate analysis of potential confounders is more informative, giving more profound and robust insight for the association, instead of crude values, adjusted OR (for crosssectional and case report studies) or HR (for cohort studies) were pooled in the analysis. The regional distribution of the studies included were as follows: nine from Asia, one from Europe and one from the USA. Eight studies reported the association between TG and urolithiasis, [21] [22] [23] [24] [25] [26] [27] [28] whereas nine studies reported the relationship between HDL and urolithiasis. [21] [22] [23] [24] [25] [26] [27] [28] [29] Three studies showed the association of any dyslipidemia traits (not separately reported TG, HDL, TC, LDL) with urolithiasis. [29] [30] [31] The detailed characteristics of included studies are presented in Table 1 .
The cut-off values of dyslipidemia traits and diagnostic tools for urolithiasis detection are shown in Table 2 . All individual studies used 150 mg/dL for a high TG cut-off value, except for the study by Masterson et al., in which no detailed information about TG was available. 29 Three studies only included men, thus only HDL for men <40 mg/dL was reported as a cut-off value in those studies. 25, 26, 31 Kohjimoto et al. reported 40 mg/dL of HDL as the cut-off value for both sexes. 30 Masterson et al. used cut-off values of <45 mg/ dL for men and <60 mg/dL for women. 29 The remaining studies were the same using HDL values of <40 mg/dL for men and <50 mg/dL for women.
The most common diagnostic tool used for the detection of urinary stone was USG. Jeong et al. 22 carried out USG plus CT, whereas Kang et al. 24 used USG plus abdominal radiography. Ando et al. used detailed questionnaire in addition to USG. 31 Masterson et al. evaluated medical records screening relevant codes for urolithiasis. 29 Kohjimoto et al. only used a Full-text articles excluded due to lack of sufficient data (n = 11)
Excluded after reading the full-texts:
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• Not report the relationship between • Reviews (n = 91) dyslipidemia and urolithiasis (n = 230) Studies included in quantitative synthesis (meta-analysis) (n = 11) • Cross-sectional studies (n = 7)
• Case-control studies (n = 1) • Cohort studies (n = 3) detailed questionnaire for kidney stone detection. 30 The mean quality of cross-sectional studies was 6.8; cohort studies were 6.3 and case-control study was 7. The details for the quality assessment of the manuscripts including total score as well as subscores of selection, comparability and outcome are shown in Table 3 .
High TG level and urolithiasis
The pooled analysis of OR of eight individual studies showed that patients with high TG levels had a higher overall adjusted estimated risk of urolithiasis (1.287 [1.073-1.544], Q = 49.731; P-value for heterogeneity <0.0001; I 2 = 85.924%). [21] [22] [23] [24] [25] [26] [27] [28] Figure 2 shows the details of the individual studies and pooled analysis including OR and CI calculations with their relative weights.
Low HDL level and urolithiasis
The pooled analysis of OR of nine individual studies showed that patients with low HDL levels had a higher overall adjusted estimated risk of urolithiasis (1.173 [1.014-1.358], Q = 42.945; P-value for heterogeneity <0.0001; I 2 = 81.371%). [21] [22] [23] [24] [25] [26] [27] [28] [29] Figure 3 shows the details of the individual studies and pooled analysis including OR and CI calculations with their relative weights.
Any component of dyslipidemia and urolithiasis
The pooled analysis of OR of three individual studies showed that patients with any dyslipidemia traits levels had a higher overall adjusted estimated risk of urolithiasis (1.309 [1.202-1.425], Q = 1.387; P-value for heterogeneity = 0.5; I 2 = 0.000%).
29-31 Figure 4 shows the details of the individual studies and pooled analysis including OR and CI calculations with their relative weights.
Subgroup analysis
Subgroup analysis was carried out according to the region and study type for the association between HDL and TG urolithiasis separately. For the association between high TG level and urolithiasis, the pooled OR for cross-sectional For the association between low HDL level and urolithiasis, the pooled OR for cross-sectional studies was 1.01 (0.91-1.13); P = 0.75, whereas for cohorts the pooled OR was 1.13 (1.04-1.23); P = 0.002. According to the region, the pooled OR was 1.15 (0.97-1.35); P = 0.1 for Asian, 1.30 (0.76-2.10); P = 0.32 for European and 1.30 (1.02-1.64); P = 0.02 for American populations.
The detailed subgroup analysis is shown in Table 4 .
Sensitivity analysis
Sensitivity analysis for the association between high TG, low HDL level and estimated risk of urolithiasis was carried out to evaluate the robustness of our meta-analysis. Each study was excluded in turn to recalculate the pooled OR of the remaining studies. For the association between high TG and estimated risk of urolithiasis, no significant change was obtained in overall pooled ORs, which ranged from 1.14 (1.01-1.28) to 1.35 (1.08-1.69) after excluding any study. Similar to the cumulative analysis, evident heterogeneity was observed, and no single study dominated the pooled ORs and heterogeneity.
For the association between low HDL and estimated risk of urolithiasis, a significant change was observed in overall pooled ORs, which ranged from 1.06 (0.97-1.16) to 1.21 (1.02-1.44) after excluding the studies of Rendina et al., 21 Kang et al., 24 Lee et al., 25 Masterson et al., 29 Jung et al. 27 and Liu et al. 28 one by one. For the association between any dyslipidemia traits and estimated risk of urolithiasis, no significant change was achieved in overall pooled ORs, which ranged from 1.23 (1.08-1.41) to 1.34 (1.21-1.47) after excluding any study. The details are shown in Table 5 .
Publication bias
The publication bias was evaluated for TG-urolithiasis and HDL-urolithiasis associations separately. 
TG-urolithiasis
The funnel plot did not show apparent asymmetry (Fig. 5) . The Begg and Mazumdar rank correlation test (P = 0.13) and Egger's regression intercept test (P = 0.10) also showed no significant publication bias was available. Using 1.01 as a criterion for trivial OR, according to Orwin's fail-safe N method calculation, 77 studies are required to bring the OR value to <1.01.
HDL-urolithiasis
The funnel plot did not show obvious asymmetry (Fig. 6) . The Begg and Mazumdar rank correlation test (P = 0.53) and Egger's regression intercept test (P = 0.32) also showed no significant publication bias. Using 1.01 as a criterion for trivial OR, according to Orwin's fail-safe N method calculation, 73 studies are required to bring the OR value to <1.01.
Discussion
We carried out the present meta-analysis by pooling individual studies to reach a more reliable and robust conclusion on the association between blood lipid profile and urolithiasis in which conflicting results are available in the literature. The term dyslipidemia mainly includes disturbances in TC, LDL, HDL and TG level. We tried to identify the association of urolithiasis with dyslipidemia traits separately as much as possible. We calculated TG-urolithiasis and HDL-urolithiasis Fig. 4 Meta-analysis plot for the association between dyslipidemia (any traits) and urolithiasis. ORs and 95% CIs of individual studies and of pooled data for the association between dyslipidemia and urolithiasis in all participants (Q = 1.387; P-value for heterogeneity = 0.5; I 2 = 0.000%). separately. Three studies presented their relationship using general term dyslipidemia, and we also estimated the dyslipidemia urolithiasis association. [29] [30] [31] Given the high prevalence of detection and the recurrence rate of urolithiasis, besides the conventional preventive methods, new therapeutic and preventive strategies should be utilized as much as possible in light of current scientific evidence. According to our overall pooled analysis, a separate association of high TG and low HDL levels with urolithiasis was found to be significant. Additionally, a strong association was found between dyslipidemia (disturbances in any serum lipid traits) and the estimated risk of urolithiasis. However, we should also take into account the subgroup analysis of TG, HDL and urolithiasis association. The subgroup analysis showed conflicting results. These results should be interpreted with caution. Dyslipidemia is a term used for patients with either enhanced TC, LDL, TG level or decreased HDL levels. Thus, the prevalence of dyslipidemia is likely to be higher compared with that of one component of dyslipidemia. This could be an explanation of the outcomes of our analysis. Additionally, given dyslipidemia is an integral part of Mets, these results suggest that stone formers should be evaluated regarding a full lipid panel.
There is a bidirectional association between urolithiasis and most cardiovascular risk factors, including hypertension and diabetes mellitus. 32 Dyslipidemia is closely related to atherosclerosis, which is the main risk factor for cardiovascular diseases. Systemic diseases and urolithiasis share similar metabolic responses and common pathophysiological mechanisms. Dyslipidemic patients are more likely to be overweight or obese. Obese individuals are found to have lower urinary pH, which is crucial for calcium oxalate and uric acid stone crystallization. Insulin resistance, the basic entity of Mets, might be of great importance as an explanatory factor for the associations between diabetes mellitus, obesity, dyslipidemia and renal stone disease. Previous studies suggested that urine pH and ammonium significantly decrease with an increasing number of Mets components. 33, 34 In an animal experiment and cell culture model study, Bobulescu et al. suggested that these responses might be associated with the lipid accumulation within the kidney, highlighting the relevance of lipid metabolism involved in the mechanisms of kidney stone formation. 35 Lifestyle habits including diet, exercise and smoking are partially well-defined, but still not a fully uncovered issue for the risk of stone formation. Naya et al. assessed various dietary fatty acids, animal fat and animal protein in 58 idiopathic stone formers in their fourth decade, and reported that the nutritional content of arachidonic acid was positively correlated with urinary oxalate excretion. 36 A correct bodyweight, regular exercise and a reduction in stressful life events are useful actions in addition to a proper diet including a high intake of fluids, fruits and vegetables, low consumption of salt and protein, and limited carbohydrate. 37 Exercise improves insulin sensitivity, the cornerstone of the association between dyslipidemia and urolithiasis, and is expected to improve Mets components. 38, 39 Renal tubular cell injury triggers crystal deposition, and lipid metabolites could be involved in the molecular mechanism of calcium oxalate crystallization in particular. Tsujihata et al. showed, in an experimental study, that atorvastatin has an inhibitory effect on renal tubular injury and oxidative stress caused by oxalate crystals, and concluded atorvastatin could help to prevent and treat crystal formation. 40 This animal model study was supported by a clinical perspective, as Sur et al. showed that statin medications had a protective effect against stone formation after adjusting for age, sex and comorbidities. 41 The results of the present analysis also provide some support for the use of antilipidemic drugs for urolithiasis, but we cannot yet suggest the use of statins as a part of preventive strategies. Additionally, even if used, the duration and dosage of these drugs for urolithiasis are under debate, and future well-designed prospective studies are necessary in this regard.
Dyslipidemia status and related conditions are mostly linked to chronic inflammation and oxidative stress. 42, 43 Davalos et al. examined the effect of oxidative stress on calcium oxalate stone and the preventive effect of anti-oxidative agents in renal tubular epithelial LLC-PK1 cells culture. 44 They concluded that oxidative stress appears to be a primary cytotoxic action of calcium oxalate monohydrate that can damage or kill renal cells, which could also lead to stone formation through the undefined cellular, physiological processes. Nephrolithiasis and accompanying comorbidities might trigger the oxidative stress cascade, which is the leading factor in cell injury. Ultimately, high calcium and phosphate or oxalate, and low citrate or magnesium in the urine might lead to crystallization in the collecting ducts of the kidney, which is oxidatively stressed and injured.
1 These mechanisms are also suggestive of the potential links between lipid metabolism disorders and kidney stone formation.
The association of various types of stone formation with altered lipid metabolism is also an important topic. Scientific evidence is relatively sparse in this regard. Inci et al. carried out a case-control study comparing the lipid profiles of 49 stone formers and 50 randomized age and sex-matched controls. 45 They showed that BMI, TC and TG levels were significantly higher in stone formers compared with the control group, and this association of BMI and TC with stone formation was more prominent in those with uric acid and calcium oxalate dihydrate calculi than in calcium oxalate monohydrate calculi. Torricelli et al. also evaluated the possible link between dyslipidemia and 24-h urine analysis and the stone composition comprising data including 2923 participants, of whom 835 had stone composition available. 46 They concluded low HDL and high TGs are associated with lower urinary pH, and uric acid stones are more common in patients with increased TC and TGs. Furthermore, two retrospective cross-sectional studies showed that the great majority of stone-forming patients with Mets produce calcium oxalate stones. 47, 48 They also showed that the percentage of uric acid stone formation was correlated with the accumulation of Mets components. We were unable to test these results in the present meta-analysis, as the individual studies lacked the stone composition and detailed 24-h urinalysis sufficient to be pooled. However, given that the basic components of the stones are calcium oxalate and uric acid, we might postulate that altered lipid components could be associated with these types of urinary stones. It is that clear future studies should also focus on the possible links between lipid metabolism profiling and various types of stone formations.
Given the studies included in the meta-analysis were all observational, we implemented the meta-analytic approaches strictly in all fields of the analysis process, including eligibility of studies, pooling and outcomes evaluation. Although the overall pooled report seems to show consistent results regarding the association between lipid parameters and urolithiasis, the subgroup analysis of TG-and HDL-urolithiasis association had conflicting findings. There are influential messages of this analysis. The stone formers should be evaluated regarding the entire content of the dyslipidemic panel (TG, HDL, LDL, TC). These results also suggest that a holistic approach is essential for stone formers comprising all individual components of Mets, including dyslipidemia, hypertension, impaired glucose metabolism and central obesity. The large number of participants (n = 282 479) included enabled the improvement of the precision of risk estimates, and allowed us to make conclusions based on this meta-analysis more precise and robust. In addition, we pooled multivariable-adjusted risk estimates to minimize the confounding factors.
There are several limitations to this analysis. The observational studies reflect only individual conditions, and cannot permit us to form a cause and effect relationship, which necessitates further prospective studies. Evident heterogeneity was found in all analyses. The different calendar period and baseline characteristics of each study population, differences for the cut-off value of dyslipidemia traits and kidney stone detection tools, and the type and extent of statistical adjustment for confounders in the individual studies might be the potential relevant sources of heterogeneity. The number of studies might seem insufficient, but we believe that rather than the number of studies included, a robust statistical analysis focusing not only on summary effect size (random or fixed), but also evaluating different aspects of the report, including heterogeneity, effect size diversion, publication bias calculation and weight distribution of the studies, could provide us more accurate meta-analysis evaluation. Furthermore, we were unable to uncover the possible association of dyslipidemia with urolithiasis according to sex stratification because of insufficient knowledge in individual studies. We were also unable to make a subgroup analysis for stone type classification, as the data from the individual studies were inadequate. Finally, we could not calculate the association of TC and LDL cholesterol with urolithiasis because of insufficient data in the studies, most of which were regarding the association between Mets and urolithiasis.
Consequently, the present meta-analysis showed that patients with higher TG and lower HDL had an increased estimated risk of urolithiasis. The TG-urolithiasis association was found to be more coherent and consistent compared with the HDL-urolithiasis association. These results should be interpreted with caution for clinical relevance. Well-designed clinical prospective studies examining the alleviating effect of antilipidemic drugs on the urolithiasis disease process could perhaps give more insight into understanding this association. Nevertheless, these data provide enough preliminary knowledge for urologists to handle urolithiasis as the manifestation of a systemic disorder implying that patients with urolithiasis should be encouraged with lifestyle modifications due to the close relationship between urolithiasis and dyslipidemia.
